MAIA Biotechnology Files Resale Prospectus For 751,879 Shares Issued Under Clinical Trial Funding Agreement
PRELIMINARY PROSPECTUSSubject to completion, dated September 25, 2026 751,879 Shares of Common Stock Pursuant to this prospectus, the selling stockholder identified herein (the "Selling Stockholder") is offering
MAIA is letting someone sell shares they got from a funding deal. When insiders sell shares, watch whether the company stays focused on its goals.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.